Abstract
Hodgkin’s and non-Hodgkin’s lymphomas (HL and NHL) are a heterogeneous group of lymphoproliferative disorders, representing the fifth most frequent type of cancer in the western world [1].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006;47(8):1326–34.
Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55(6):368–76.
Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol. 2005;23(26):6400–8.
Juweid ME. FDG-PET/CT in lymphoma. Methods Mol Biol. 2011;727:1–19.
Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111(2):504–16.
Bodet-Milin C, et al. FDG-PET in follicular lymphoma management. J Oncol. 2012;370272(10):30.
Park S, et al. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. Am J Hematol. 2012;87(9):937–40.
Shelly MJ, et al. 18-Fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin’s B-cell lymphoma. ISRN Hematol. 2012;456706(10):11.
Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:317.
Hosein PJ, et al. Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol. 2011;86(10):841–5.
Zinzani PL. PET in T-cell lymphoma. Curr Hematol Malig Rep. 2011;6(4):241–4.
Cimarelli S, et al. Use of F-18 FDG PET/CT in non-Hodgkin lymphoma with central nervous system involvement. Clin Nucl Med. 2011;36(6):e45–9.
Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008;10(2):223–8.
Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507–16.
Kaplan WD, et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol. 1990;8(12):1966–70.
Tsukamoto N, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110(3):652–9.
Karam M, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107(1):175–83.
Kostakoglu L, et al. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012;53(11):2143–50.
Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104(5):1066–74.
Munker R, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin’s disease. Ann Oncol. 2004;15(11):1699–704.
Nievelstein RA, et al. Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma. Eur Radiol. 2012;22(9):1946–54.
Brix G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46(4):608–13.
Fahey FH. Dosimetry of pediatric PET/CT. J Nucl Med. 2009;50(9):1483–91.
Lauenstein TC, Semelka RC. Emerging techniques: whole-body screening and staging with MRI. J Magn Reson Imaging. 2006;24(3):489–98.
Schmidt GP, et al. High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest Radiol. 2007;42(6):449–59.
Lauenstein TC, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233(1):139–48.
Antoch G, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290(24):3199–206.
Brennan DD, et al. A comparison of whole-body MRI and CT for the staging of lymphoma. AJR Am J Roentgenol. 2005;185(3):711–16.
Kellenberger CJ, et al. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol. 2004;14(10):1829–41.
Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188(6):1622–35.
Szafer A, et al. Diffusion-weighted imaging in tissues: theoretical models. NMR Biomed. 1995;8(7–8):289–96.
Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000;43(6):828–36.
Barajas Jr RF, et al. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2010;31(1):60–6.
Gu J, et al. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol. 2011;197(3):W384–91.
Abdulqadhr G, et al. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol. 2011;52(2):173–80.
van Ufford HM, et al. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol. 2011;196(3):662–9.
Punwani S, et al. Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? Eur J Nucl Med Mol Imaging. 2012;30:30.
Kwee TC, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol. 2009;44(10):683–90.
Baraniskin A, et al. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol. 2012;156(4):421–32.
Haldorsen IS, et al. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol. 2005;44(7):728–34.
Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am. 2005;19(4):597–609.
Haldorsen IS, et al. CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. AJNR Am J Neuroradiol. 2009;30(4):744–51.
Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32(6):984–92.
Go JL, Lee SC, Kim PE. Imaging of primary central nervous system lymphoma. Neurosurg Focus. 2006;21(5):E4.
Kosaka N, et al. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol. 2008;190(6):W365–9.
Westwood TD, Hogan C, Julyan PJ, Coutts G, Bonington S, Carrington B, Taylor B, Khoo S, Bonington A. Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Eur J Radiol. 2013;82(8):e374–9. doi:10.1016/j.ejrad.2013.03.008. pii: S0720-048X(13)00137-X.
Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, Hader C, Weber WA, Illerhaus G, Meyer PT. 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med. 2013;54(2):184–91. doi:10.2967/jnumed.112.108654. Epub 2012 Dec 18.
Jang SJ, Lee KH, Lee JY, Choi JY, Kim BT, Kim SJ, Kim WS. (11)C-methionine PET/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate. Clin Nucl Med. 2012;37(10):e241–4.
Shi X, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med. 2013;38(2):98–102. doi:10.1097/RLU.0b013e318279b6cc.
Pelosi E, et al. FDG-PET in the detection of bone marrow disease in Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging. 2008;52(1):9–16.
Moog F, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16(2):603–9.
Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46(6):958–63.
Cronin CG, et al. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010;194(1):W91–103.
Mirowitz SA, et al. MR imaging of bone marrow lesions: relative conspicuousness on T1-weighted, fat-suppressed T2-weighted, and STIR images. AJR Am J Roentgenol. 1994;162(1):215–21.
Yasumoto M, et al. MR detection of iliac bone marrow involvement by malignant lymphoma with various MR sequences including diffusion-weighted echo-planar imaging. Skeletal Radiol. 2002;31(5):263–9.
Kwee TC, de Klerk JM, Nievelstein RA. Imaging of bone marrow involvement in lymphoma: state of the art and future directions. Scientific World Journal. 2011;11:391–402.
Drzezga A, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53(6):845–55.
Platzek I, et al. PET/MR for therapy response evaluation in malignant lymphoma: initial experience. MAGMA. 2012;16:16.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gaeta, M.C., Herrmann, K.A. (2014). PET/MRI in Evaluating Lymphomas: Preliminary Experience and Potential Future Applications. In: Carrio, I., Ros, P. (eds) PET/MRI. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40692-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-40692-8_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40691-1
Online ISBN: 978-3-642-40692-8
eBook Packages: MedicineMedicine (R0)